Accordingly, a significant reduction in collagen type XI alpha 1 (COL11A1) levels could also be observed in BBIT20-treated tumours (Fig. 8E and G), a collagen subtype typically overexpressed in PDAC that is associated with tumour progression, metastasis and poor prognosis [59]. The gene discussed is COL11A1; the disease is neoplasm.